keyword
MENU ▼
Read by QxMD icon Read
search

Latanoprost

keyword
https://www.readbyqxmd.com/read/28203189/a-mystery-of-bilateral-annular-choroidal-and-exudative-retinal-detachment-with-no-systemic-involvement-is-it-part-of-vogt-koyanagi-harada-disease-spectrum-or-a-new-entity
#1
Ibrahim Elaraoud, Walter Andreatta, Li Jiang, Kenan Damer, Jalil Al-Ibrahim
A 65-year-old Caucasian male presented to the eye emergency department with bilateral significant visual loss. He was otherwise healthy with no significant past medical history. Ophthalmic history was significant for chronic open-angle glaucoma, for which the patient was using latanoprost once daily to both eyes. There was no preceding history of trauma or ocular surgery and the patient was emmetropic. Two weeks prior to his presentation, he reported a headache, which settled spontaneously. Slit-lamp examination demonstrated bilateral keratic precipitates, bilateral significantly shallow anterior chamber, and bilaterally normal intraocular pressures of 16 mm Hg...
January 2017: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/28165835/assessment-of-the-anterior-chamber-flare-and-macular-thickness-in-patients-treated-with-topical-antiglaucomatous-drugs
#2
Fırat Selen, Oya Tekeli, Özge Yanık
PURPOSE: To determine the changes in the anterior chamber flare and central macular thickness (CMT) under topical antiglaucomatous therapy. METHODS: This study included 121 eyes of 73 patients and 36 eyes of 18 controls. Glaucoma patients were divided into 3 groups (timolol maleate, latanoprost, and bimatoprost). Control eyes did not receive any medications. Flare and CMT measurements were performed at baseline and follow-up visits (15th day, and 1st, 3rd, 6th, and 12th month)...
February 6, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28164422/effect-of-prophylactic-topical-hypotensive-medications-in-reducing-the-incidence-of-postoperative-ocular-hypertension-after-phacoemulsification-in-dogs
#3
D Dustin Dees, Kate J Spahn, Lynsey Smith Wagner, Andrew Greller, Danielle Paglia, Micki D Armour, Richard Madsen
OBJECTIVE: To determine whether topical hypotensive medications prevent postoperative ocular hypertension (POH) after phacoemulsification. ANIMALS STUDIED: 52 client-owned dogs (88 eyes). PROCEDURES: Diabetic and nondiabetic dogs having undergone phacoemulsification were included in this retrospective study. The control group received no ocular hypotensive medications. The treatment groups received latanoprost, dorzolamide, or dorzolamide/timolol, beginning immediately after surgery, for 2-week duration...
February 6, 2017: Veterinary Ophthalmology
https://www.readbyqxmd.com/read/28146132/a-novel-convergent-synthesis-of-the-potent-antiglaucoma-agent-tafluprost
#4
Małgorzata Krupa, Michał Chodyński, Anna Ostaszewska, Piotr Cmoch, Iwona Dams
Tafluprost (AFP-168, 5) is a unique 15-deoxy-15,15-difluoro-16-phenoxy prostaglandin F2α (PGF2α) analog used as an efficacious ocular hypotensive agent in the treatment of glaucoma and ocular hypertension, as monotherapy, or as adjunctive therapy to β-blockers. A novel convergent synthesis of 5 was developed employing Julia-Lythgoe olefination of the structurally advanced prostaglandin phenylsulfone 16, also successfully applied for manufacturing of pharmaceutical grade latanoprost (2), travoprost (3) and bimatoprost (4), with an aldehyde ω-chain synthon 17...
January 31, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/28081184/intraocular-pressure-lowering-effect-of-latanoprost-is-hampered-by-defective-cervical-lymphatic-drainage
#5
Young Kook Kim, Kyeong Ik Na, Jin Wook Jeoung, Ki Ho Park
PURPOSE: To evaluate whether defects in cervical lymphatic drainage influence the intraocular pressure (IOP)-lowering effect of latanoprost in patients with primary open-angle glaucoma (POAG) who have undergone unilateral radical neck dissection (uRND). METHODS: We enrolled (1) bilateral POAG patients who had started (bilateral) latanoprost (0.005%) monotherapy prior to their uRND and (2) treatment-naïve, bilateral glaucoma suspects (GSs) who had undergone the same surgery...
2017: PloS One
https://www.readbyqxmd.com/read/28053501/fixed-combination-of-travoprost-and-timolol-maleate-reduces-intraocular-pressure-in-japanese-patients-with-primary-open-angle-glaucoma-or-ocular-hypertension-analysis-by-prostaglandin-analogue
#6
Tadashi Nakano, Shiro Mizoue, Nobuo Fuse, Aiko Iwase, Shun Matsumoto, Keiji Yoshikawa
BACKGROUND: We have shown a decrease in mean intraocular pressure (IOP) by switching to travoprost/timolol fixed combination (TTFC) in subjects receiving prostaglandin analogue (PGA) monotherapy and requiring additional medication in a previous report. For analyzing factors affecting IOP reduction, baseline IOP and preceding PGA were selected as statistically and clinically significant factors. In this report, we examine IOP-lowering effect and adverse drug reactions by preceding PGA...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27994439/impact-of-prostaglandin-glaucoma-drops-on-platelet-activating-factor-action-an-in-vitro-study
#7
Marilita M Moschos, Eirini Nitoda, Irini P Chatziralli, Georgios D Panos, Constantinos A Demopoulos
AIM: The aim of this study was to investigate the effect of different prostaglandin analogs on platelet-activating factor (PAF) levels. METHODS: Three prostaglandin analogs were selected: bimatoprost 0.3 mg/mL, latanoprost 50 μg/mL, and tafluprost 15 μg/mL. Each drug sample was tested for its ability to cause platelet aggregation, which was measured as PAF-induced aggregation, before and after the addition of various concentrations of the examined sample, creating a linear curve of percentage inhibition (ranging from 0% to 100%) versus different concentrations of the sample...
2016: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/27913991/24-hour-efficacy-and-ocular-surface-health-with-preservative-free-tafluprost-alone-and-in-conjunction-with-preservative-free-dorzolamide-timolol-fixed-combination-in-open-angle-glaucoma-patients-insufficiently-controlled-with-preserved-latanoprost-monotherapy
#8
Anastasios-Georgios Konstas, Konstadinos G Boboridis, Paraskevas Kapis, Konstantinos Marinopoulos, Irini C Voudouragkaki, Dimitrios Panayiotou, Dimitrios G Mikropoulos, Eirini Pagkalidou, Anna-Bettina Haidich, Andreas Katsanos, Luciano Quaranta
INTRODUCTION: The aim of the present study was to evaluate the 24-h efficacy, tolerability, and ocular surface health with preservative-free (PF) tafluprost and a PF triple drug regimen comprising tafluprost and dorzolamide/timolol fixed combination (DTFC) in open-angle glaucoma patients who were insufficiently controlled with preserved branded or generic latanoprost monotherapy and who exhibited signs or symptoms of ocular surface disease (OSD). METHODS: Prospective, observer-masked, crossover, comparison...
January 2017: Advances in Therapy
https://www.readbyqxmd.com/read/27862086/correlations-of-afap1-gmds-and-ptgfr-gene-polymorphisms-with-intra-ocular-pressure-response-to-latanoprost-in-patients-with-primary-open-angle-glaucoma
#9
X-J Cui, A-G Zhao, X-L Wang
WHAT IS KNOWN AND OBJECTIVE: Genomewide association studies have identified a number of genetic variants that are associated with the development of primary open-angle glaucoma (POAG). This study aimed to explore possible correlations of common single nucleotide polymorphisms (SNPs) in AFAP1, GMDS and PTGFR genes with intra-ocular pressure (IOP) response to latanoprost in POAG patients. METHODS: From January 2012 to December 2014, 135 patients with POAG were enrolled into our study...
February 2017: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/27859240/the-neuroprotective-effect-of-latanoprost-acts-via-klotho-mediated-suppression-of-calpain-activation-after-optic-nerve-transection
#10
Kotaro Yamamoto, Kota Sato, Masayoshi Yukita, Masayuki Yasuda, Kazuko Omodaka, Morin Ryu, Kosuke Fujita, Koji M Nishiguchi, Shigeki Machida, Toru Nakazawa
Latanoprost was first developed for use in glaucoma therapy as an ocular hypotensive agent targeting the prostaglandin F2α (FP) receptor. Subsequently, latanoprost showed a neuroprotective effect, an additional pharmacological action. However, although it is well-known that latanoprost exerts an ocular hypotensive effect via the FP receptor, it is not known whether this is also true of its neuroprotective effect. Klotho was firstly identified as the gene linked to the suppression of aging phenotype: the defect of klotho gene in mice results aging phenotype such as hypokinesis, arteriosclerosis, and short lifespan...
November 15, 2016: Journal of Neurochemistry
https://www.readbyqxmd.com/read/27829990/analysis-of-the-effects-of-preservative-free-tafluprost-on-the-tear-proteome
#11
Sebastian Funke, Sabine Beck, Katrin Lorenz, Marion Kotterer, Dominik Wolters, Natarajan Perumal, Norbert Pfeiffer, Franz H Grus
The purpose of the present study was to assess the ocular surface health status in primary open angle glaucoma (POAG) patients switching from topical application of preserved latanoprost (LT) to preservative-free tafluprost (PFT) by tear proteomic monitoring. Tear fluid of POAG patients showing dry eye symptoms, using LT and switching to PFT as well as tear fluid of healthy controls has been examined. Tear proteome dynamics was monitored over 24 weeks in a first mass spectrometric explorative analysis in a small POAG patient cohort (N = 3)...
2016: American Journal of Translational Research
https://www.readbyqxmd.com/read/27828896/new-classes-of-glaucoma-medications
#12
Emily M Schehlein, Gary D Novack, Alan L Robin
PURPOSE OF REVIEW: To discuss recent advances in the medical management of glaucoma and to highlight future medical therapies currently in development. RECENT FINDINGS: In 1996, latanoprost (Xalatan) was approved in the United States as a new chemical entity and new class (prostaglandin analogs) for the topical treatment of ocular hypertension and glaucoma. In the period from the late 1990s-2010s, while there were additional new chemical entities, fixed dose combinations, and formulation improvements, there were no new classes of ocular hypotensive medications approved worldwide...
March 2017: Current Opinion in Ophthalmology
https://www.readbyqxmd.com/read/27828721/change-in-central-corneal-thickness-after-the-discontinuation-of-latanoprost-in-normal-tension-glaucoma-change-in-central-corneal-thickness-after-stop-of-latanoprost
#13
Romi Yoo, Youn A Choi, Byung Joo Cho
PURPOSE: To assess the impact of latanoprost on central corneal thickness (CCT) after ceasing medication in patients with normal tension glaucoma (NTG). METHODS: A total of 46 eyes from 46 NTG patients, and 44 eyes from 44 individuals with glaucoma suspect (controls), were included in this retrospective study. Newly diagnosed early NTG patients (visual field mean deviation >-6.00) were administered latanoprost 0.005% monotherapy once a day. CCTs were measured by ultrasound pachymetry before treatment, for 5 years during treatment, and for 2 years after ceasing treatment...
January 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27800256/transpupillary-argon-laser-cyclophotocoagulation-in-a-refractory-traumatic-glaucoma-patient-with-aphakia-and-aniridia
#14
Umut Duygu Uzunel, Berna Yüce, Tuncay Küsbeci, Halil Ateş
We present a case of transpupillary argon laser cyclophotocoagulation (TALC) in a patient with traumatic aniridia and aphakia secondary to blunt trauma who had previous bilateral trabeculectomy. Four months after the trauma the patient's intraocular pressure (IOP) rose to 35 mmHg despite topical antiglaucomatous medication. Inferior 180 degrees cyclophotocoagulation was performed with transpupillary argon laser in the first session and his IOP fell to values of 12-17 mmHg. Twelve weeks after TALC, his IOP rose to 22 mmHg and we had to apply TALC to the residual ciliary processes...
January 2016: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/27799736/efficacy-and-tolerability-of-benzalkonium-chloride-free-travoprost-in-glaucoma-patients-switched-from-benzalkonium-chloride-preserved-latanoprost-or-bimatoprost
#15
Julian García-Feijoo, Francisco J Muñoz-Negrete, Douglas A Hubatsch, Gemma C Rossi
INTRODUCTION: The preservative benzalkonium chloride (BAK) is used to preserve several topical, intraocular pressure (IOP)-lowering glaucoma medications but can cause tolerability concerns that may lead to decreased adherence to treatment and ultimately diminish the effectiveness of IOP control. The study aimed to determine the efficacy and tolerability of BAK-free travoprost preserved with polyquaternium-1 in glaucoma patients switched from BAK-preserved latanoprost or bimatoprost. METHODS: This 12-week, open-label study was conducted in Europe between December 2011 and February 2013...
2016: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27791324/effect-of-topical-ophthalmic-latanoprost-0-005-solution-alone-and-in-combination-with-diclofenac-0-1-solution-in-healthy-horses-a-pilot-study
#16
Kyle Tofflemire, Elizabeth M Whitley, Rachel Allbaugh, Gil Ben-Shlomo, Angela Griggs, Travis Strong, R David Whitley
OBJECTIVE: To evaluate the effect of topical ophthalmic 0.005% latanoprost alone and in combination with 0.1% diclofenac on healthy horses. ANIMALS STUDIED: Twelve healthy adult horses. PROCEDURES: A randomized, masked crossover design was used with horses divided into three groups for once daily treatment in one randomly selected eye. For arm 1 of the study, Group D (n = 3) received 0.1% diclofenac, Group L (n = 3) received 0.005% latanoprost, and Group DL (n = 6) received 0...
October 28, 2016: Veterinary Ophthalmology
https://www.readbyqxmd.com/read/27767427/effects-of-perioperative-topical-dorzolamide-hydrochloride-timolol-maleate-administration-on-incidence-and-severity-of-postoperative-ocular-hypertension-in-dogs-undergoing-cataract-extraction-by-phacoemulsification
#17
Rachel B Matusow, Ian P Herring, J Phillip Pickett, Natalia Henao-Guerrero, Stephen R Werre
OBJECTIVE To assess the effects of topically applied 2% dorzolamide hydrochloride-0.5% timolol maleate ophthalmic solution (DHTM) on incidence and severity of postoperative ocular hypertension (POH; ie, intraocular pressure [IOP] > 25 mm Hg) in dogs undergoing cataract extraction by phacoemulsification. DESIGN Randomized, masked, controlled study. ANIMALS 103 dogs (180 eyes). PROCEDURES Pertinent history, signalment, and ophthalmic examination findings were recorded. Dogs received 1 drop of DHTM or sham treatment solution (sterile, buffered, isotonic eye drops) in both eyes 14 hours and 2 hours before anesthetic induction and at the time of corneal incision closure (ie, end of surgery); IOPs were assessed by rebound tonometry 2, 4, 6, and 8 hours after surgery and between 7:30 and 8:00 am on the following day...
November 1, 2016: Journal of the American Veterinary Medical Association
https://www.readbyqxmd.com/read/27764023/sustained-drug-delivery-for-glaucoma-current-data-and-future-trends
#18
Ahmad A Aref
PURPOSE OF REVIEW: Sustained drug delivery has been recognized as a need for patients with ocular hypertension or glaucomatous optic neuropathy. Several sustained drug delivery systems and devices are currently on the horizon. This review aims to summarize initial results with these platforms, as reported in the literature, and also provide insight into their possible role in the glaucoma treatment paradigm. RECENT FINDINGS: Sustained drug delivery systems currently on the horizon include the topical bimatoprost ocular insert, travoprost and latanoprost punctal plugs, latanoprost-eluting contact lenses, bimatoprost and travoprost intraocular implants, as well as several other therapies in earlier stages of development...
March 2017: Current Opinion in Ophthalmology
https://www.readbyqxmd.com/read/27749098/cytotoxic-effect-of-latanoprost-on-human-corneal-stromal-cells-in-vitro-and-its-possible-mechanisms
#19
Jun-Wei Shen, Ming Shan, Yuan-Yuan Peng, Ting-Jun Fan
PURPOSE: To investigate the cytotoxic effect of latanoprost on corneal stroma and its underlying cellular and molecular mechanisms using non-transfected human corneal stromal (HCS) cells as an in vitro model. METHODS: After HCS cells were treated with latanoprost at concentrations varying from 50 mg/l (clinical therapeutic dosage) to 0.78125 mg/l, and cell morphology, cell viability, and cell cycle were detected by light microscopy, methyl thiazolyl tetrazolium assay, and flow cytometry (FCM) with propidium iodide (PI) staining, respectively...
October 17, 2016: Current Eye Research
https://www.readbyqxmd.com/read/27601879/comparison-study-of-intraocular-pressure-reduction-efficacy-and-safety-between-latanoprost-and-tafluprost-in-japanese-with-normal-tension-glaucoma
#20
Yoko Ikeda, Kazuhiko Mori, Kaori Tada, Morio Ueno, Shigeru Kinoshita, Chie Sotozono
PURPOSE: To evaluate and compare the intraocular pressure (IOP) reduction efficacy and safety between the ophthalmic solutions 0.005% latanoprost (Lat) and 0.0015% tafluprost (Taf) in Japanese patients with normal-tension glaucoma (NTG). METHODS: In this randomized nonmasked study, we prospectively enrolled 30 Japanese NTG patients who had used Lat monotherapy for more than 4 weeks, and randomly divided them into the following two groups: 1) Lat-to-Taf group (LT group) and 2) Taf-to-Lat group (TL group)...
2016: Clinical Ophthalmology
keyword
keyword
121100
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"